Time to first renal flare for combinations of belimumab and AMA in the pooled study population. Survival curves and hazards ratios comparing patients receiving different belimumab doses in combination with AMA (solid lines) and without AMA (dashed lines). Patients from BLISS-52, BLISS-SC and BLISS-NEA were censored at week 52, whereas patients from BLISS-76 were censored at week 76. AMA: antimalarial agents; BLM: belimumab; IV: intravenous; SC: subcutaneous